Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The therapeutic potential of glucagon-like peptide-1 (GLP-1) in improving glycaemic control in diabetes has been widely studied, but the potential beneficial effects of glucose-dependent insulinotropic polypeptide (GIP) have until recently been almost overlooked. One of the major problems, however, in exploiting either GIP or GLP-1 as potential therapeutic agents is their short duration of action, due to enzymatic degradation in vivo by dipeptidylpeptidase IV (DPP IV). Therefore, this study examined the plasma stability, biological activity and antidiabetic potential of two novel NH2-terminal Ala2-substituted analogues of GIP, containing glycine (Gly) or serine (Ser). Following incubation in plasma, (Ser2)GIP had a reduced hydrolysis rate compared with native GIP, while (Gly2)GIP was completely stable. In Chinese hamster lung fibroblasts stably transfected with the human GIP receptor, GIP, (Gly2)GIP and (Ser2)GIP stimulated cAMP production with EC(50) values of 18.2, 14.9 and 15.0 nM respectively. In the pancreatic BRIN-BD11 beta-cell line, (Gly2)GIP and (Ser2)GIP (10(-8) M) evoked significant increases (1.2- and 1.5-fold respectively; P<0.01 to P<0.001) in insulinotropic activity compared with GIP. In obese diabetic ob/ob mice, both analogues significantly lowered (P<0.001) the glycaemic excursion in response to i.p. glucose. This enhanced glucose-lowering ability was coupled to a significantly raised (P<0.01) and more protracted insulin response compared with GIP. These data indicate that substitution of the penultimate Ala2 in GIP by Gly or Ser confers resistance to plasma DPP IV degradation, resulting in enhanced biological activity, therefore raising the possibility of their use in the treatment of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis
Bray, G. A., & York, D. A. (1979) · Physiological Reviews · doi:10.1152/physrev.1979.59.3.719 · Cited by 1,132
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 1×
“In blood, both GIP and GLP-1 are rapidly degraded by DPP IV, resulting in short biological half-lives in vivo (Kieffer et al. 1995) and greatly diminished therapeutic potential.”
BackgroundMoens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250
Functional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219 · cited 1×
“Furthermore, functional GIP receptors have been identified on adipocytes (Yip et al. 1998) and have been shown to stimulate glucose transport (Eckel et al. 1979), increase fatty acid synthesis (Oben et al. 1991) and stimulate lipoprotein lipase activity (Knapper et al. 1995).”
BackgroundLu, M., Wheeler, M. B., Leng, X. H., & Boyd, A. E. (1993) · Endocrinology · doi:10.1210/endo.132.1.8380389 · Cited by 151 · cited 3×
“2001) and amplification of intracellular Ca concentrations (Lu et al. 1993).”
BackgroundO'Harte, F., Gray, A., & Flatt, P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1560237 · Cited by 60 · cited 5×
“Furthermore, NH2-terminal glucitol-GIP displayed markedly enhanced insulinotropic potency in clonal pancreatic -cells and improved in vivo biological activity in animals with type 2 diabetes (O’Harte et al. 1998b, 2000).”
BackgroundResultInfluentialSelf-citation
Cited by
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125
“Whilst GIP mimetics have not entered clinical development, pre-clinical studies clearly demonstrate that Nterminally modified and acylated GIP peptides exhibit improved DPP-IV resistance, enhanced glucose-lowering and insulin-releasing actions in animal models of obesity-diabetes [19-29].”
BackgroundSelf-citationGreen, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382774 · Cited by 111
Self-citationMechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94
Wang, L. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s358989 · Cited by 56
Metadata
- Authors
- Gault, V., Flatt, P., Harriott, P., Mooney, M., Bailey, C., & O'Harte, F.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2003-01-01
- Volume
- 176
- Issue
- 1
- Pages
- 133-141
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2105096600
- Cited by
- 38
- References
- 7
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. https://app.cochat.ai/papers/10.1677/joe.0.1760133
- The paper
- Gault, V., Flatt, P., Harriott, P., Mooney, M., Bailey, C., & O'Harte, F. (2003). Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. Journal of Endocrinology. https://doi.org/10.1677/joe.0.1760133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.